Every 8-K that Bridgebio Pharma (BBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBIO filings page.
BridgeBio Pharma, Inc. (BBIO) announced a voluntary agreement with the U.S. government intended to expand access to its medicines and lower costs for American patients, particularly those with rare genetic diseases. As part of the agreement, BridgeBio plans to expand state Medicaid access to its currently marketed medicine via the GENEROUS Model, building on existing patient support programs such as ForgingBridges®, which can reduce qualifying patients’ out-of-pocket costs to as little as $0 per month.
BridgeBio states that it does not expect to be subject to future pricing mandates and that its pricing commitment for future medicines is expected to exclude products approved exclusively for orphan indications. The agreement does not affect coverage of Attruby through Medicare Part D or the ForgingBridges copay assistance program. The company also highlights three additional medicines under FDA review for rare genetic conditions, with priority review PDUFA dates in late 2026 and 2027.
BridgeBio Pharma, Inc. reported that existing shareholder KKR Genetic Disorder L.P. is conducting a secondary public offering of 5,000,000 shares of BridgeBio common stock. An Underwriting Agreement with William Blair & Company, Goldman Sachs & Co. LLC and KKR Capital Markets LLC covers the sale at a public offering price of $78.00 per share. The shares are being sold by the selling stockholder, and BridgeBio is not selling any shares and will not receive any of the proceeds. The offering is being made under an automatic shelf registration statement on Form S-3ASR, with the transaction expected to close on August 17, 2026, subject to customary conditions.
BridgeBio Pharma reported strong top-line growth for the quarter ended June 30, 2026, while remaining loss-making as it invests heavily in commercialization and late-stage R&D. Total revenues were $243.7 million, up from $110.6 million a year earlier, driven mainly by $222.4 million in U.S. Attruby net product revenue and higher royalties from BEYONTTRA in the EU and Japan.
Total operating costs and expenses rose to $350.8 million from $244.8 million, reflecting increased SG&A for the Attruby launch and pre-commercial spend for pipeline programs, plus higher R&D. Net loss attributable to common stockholders narrowed to $152.2 million, or $0.78 per share, compared to $181.9 million, or $0.95, in 2025.
Cash, cash equivalents and marketable securities were $720.2 million as of June 30, 2026, excluding a subsequent $1 billion preferred equity financing that closed July 1, 2026. Strategically, all three key NDAs are now in or submitted for FDA review, with PDUFA dates for BBP‑418 on November 27, 2026 and encaleret on May 8, 2027, and an NDA for oral infigratinib filed in achondroplasia.
BridgeBio Pharma, Inc. announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1), assigning a PDUFA target action date of May 8, 2027 and indicating it is not currently planning an advisory committee meeting.
The Phase 3 CALIBRATE trial of encaleret in ADH1 achieved all pre-specified primary and key secondary endpoints, and BridgeBio is enrolling the CALIBRATE-PEDS Phase 2/3 pediatric study and preparing a Phase 3 trial in chronic hypoparathyroidism. As of April 2026, over 2,100 individuals in the U.S. have been diagnosed with autosomal dominant hypocalcemia since October 2023 based on claims data, and the company plans to submit a European MAA for encaleret in the second half of 2026.
BridgeBio Pharma entered into a $933.9 million preferred equity financing with funds managed by Sixth Street and HealthCare Royalty. The investors bought 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock at $1,000 per share, with Sixth Street providing $800 million and HealthCare Royalty $133.9 million.
The preferred stock carries a 7% annual cumulative dividend on the accrued amount, payable quarterly in cash or by adding to principal, with step-ups over time up to a 17% cap and additional increases upon certain events. It is initially convertible into common stock at $137.79 per share, with an aggregate initial conversion into 6,777,705 common shares, and ranks senior to common stock for dividends and liquidation. The company may force conversion or redeem the preferred after set anniversaries under specified price and return thresholds, while holders gain voting rights on an as-converted basis and significant protective provisions. BridgeBio also agreed to file a resale shelf registration for the underlying common shares and to seek stockholder approval by June 30, 2027, if required for full conversion.
BridgeBio Pharma, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders elected three Class I directors to serve until the 2029 annual meeting. Director Randal W. Scott resigned at the end of his term, and the company stated his resignation was not due to any disagreement.
Stockholders approved, on an advisory basis, the compensation of named executive officers and chose an annual frequency for future say‑on‑pay votes. They also ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026.
Shareholders approved an amendment and restatement of the 2021 Stock Option and Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 2,000,000 shares.
BridgeBio Pharma announced that the FDA has accepted and granted Priority Review to its New Drug Application for oral BBP-418, targeting limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The FDA set a PDUFA target action date of November 27, 2026 and is not currently planning to hold an advisory committee meeting.
If approved, BBP-418 would be the first and only therapy for people living with LGMD2I/R9 and the first approved treatment for any form of limb-girdle muscular dystrophy, addressing a significant unmet need. In the Phase 3 FORTIFY trial, BBP-418 met all primary and secondary endpoints, with treated patients improving on key measures while placebo patients declined.
BBP-418 has Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA and Orphan Drug designation from the EMA. BridgeBio plans additional studies in younger LGMD2I/R9 patients and in related LGMD2M/R13 and LGMD2U/R20 indications.
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret as a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). In the Phase 3 CALIBRATE trial, encaleret met all pre-specified primary and key secondary efficacy endpoints.
At Week 24, 76% of participants on encaleret achieved both serum and urine calcium within target ranges, compared with 4% on conventional therapy at Week 4 (p<0.0001). The company states that encaleret may be eligible for priority review and that it anticipates a potential U.S. launch in early 2027, if approved.
BridgeBio plans additional regulatory and development steps, including a Marketing Authorization Application to the EMA for ADH1 in the second half of 2026, ongoing enrollment of the CALIBRATE-PEDS pediatric ADH1 study, and initiation of the -HP Phase 3 study in chronic hypoparathyroidism in Summer 2026. Encaleret has Fast Track and Orphan Drug designations in multiple regions.
BridgeBio Pharma, Inc. entered into a new Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC to establish an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock with an aggregate offering price of up to $500,000,000 through these sales agents on Nasdaq or other existing markets.
The sales agents will use commercially reasonable efforts on a best efforts basis, and BridgeBio will pay them a commission of up to 3.0% of gross proceeds on any shares sold. In connection with the new arrangement, BridgeBio and the agents agreed to terminate their prior Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026.
BridgeBio Pharma reported strong first-quarter 2026 growth while remaining unprofitable and launched a major buyback. Total revenue reached $194.5 million, up from $116.6 million a year earlier, driven by $180.6 million in U.S. Attruby net product revenue and higher royalties from BEYONTTRA in Europe and Japan.
Total operating costs and expenses rose to $300.5 million as the company invested in Attruby commercialization and late-stage pipeline programs, leading to a net loss of $166.6 million, or $0.84 per share, similar to the prior year. Cash, cash equivalents, and marketable securities were $940.2 million as of March 31, 2026, bolstered by new convertible note financing.
The board approved a stock repurchase program of up to $500 million of common stock, which can be executed over time at management’s discretion. BridgeBio highlighted real-world and clinical data supporting Attruby, reported an NDA submission for BBP‑418 in LGMD2I/R9, and outlined plans to file NDAs for encaleret and oral infigratinib in 2026, positioning three programs for potential launches in 2026–2027.
BridgeBio Pharma submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The filing is supported by the Phase 3 FORTIFY trial’s 12‑month interim analysis, which met all pre‑specified primary and secondary endpoints.
Interim data showed rapid, consistent treatment effects, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio expects, if approved, a potential U.S. launch in late 2026 or early 2027 and notes BBP-418 could become the first approved therapy for LGMD2I/R9 and potentially any form of limb-girdle muscular dystrophy.
BridgeBio Pharma reported strong 2025 revenue growth but remains deeply loss-making as it scales commercial and late‑stage programs. Total revenues, net reached $502.1 million for 2025, up from $221.9 million in 2024, driven largely by $362.4 million in Attruby net product revenue and higher royalties from BEYONTTRA.
Operating costs and expenses climbed to $1.03 billion, mainly from a $242.3 million increase in selling, general and administrative spending to support launches, partially offset by lower R&D. Net loss attributable to common stockholders widened to $724.9 million with loss per share of $3.78.
Cash, cash equivalents and marketable securities were $587.5 million at year-end. The company issued $575.0 million of 2031 notes, executed a $300.0 million royalty deal, repaid a $459.0 million term loan and repurchased $48.3 million of stock. BridgeBio highlighted three positive Phase 3 readouts (BBP-418, encaleret, infigratinib) and is planning multiple NDA submissions beginning in the first half of 2026.
BridgeBio Pharma reported positive topline Phase 3 results from its PROPEL 3 trial of oral infigratinib in children with achondroplasia. The study met its primary endpoint, showing a statistically significant improvement in annualized height velocity at Week 52 (p<0.0001), with a mean treatment difference versus placebo of +2.10 cm/year and an LS mean of +1.74 cm/year.
The trial also met a key secondary endpoint, improving height Z-score, and showed the first statistically significant improvement in body proportionality versus placebo in children younger than 8 years. Oral infigratinib was generally well tolerated, with no treatment-related serious adverse events or discontinuations reported.
Based on these results, BridgeBio plans to submit a New Drug Application and Marketing Authorization Application for infigratinib for achondroplasia in the second half of 2026 and to accelerate development in hypochondroplasia, including ongoing and planned Phase 3 programs.
BridgeBio Pharma completed a private offering of $632.5 million in 0.75% Convertible Senior Notes due 2033 to qualified institutional buyers under Rule 144A. The notes pay 0.75% interest semiannually, mature on February 1, 2033, and can be settled in cash, stock, or a combination at the company’s election.
BridgeBio received approximately $619.3 million in net proceeds, which it plans to use mainly to repurchase, settle conversion obligations for, or repay a portion of its 2.50% Convertible Senior Notes due 2027, as well as for general corporate purposes. Concurrently with the closing, it used about $82.5 million of cash on hand to repurchase 1,081,825 shares of common stock at $76.26 per share from certain note purchasers.
The initial conversion rate is 9.0435 shares per $1,000 principal amount (an initial conversion price of about $110.58 per share), with potential adjustment and an increased rate in certain corporate events. A maximum of 8,293,972 shares may initially be issued upon conversion based on a maximum conversion rate of 13.1130 shares per $1,000 principal amount.
BridgeBio Pharma furnished an update with preliminary, unaudited financial figures for the quarter and fiscal year ended December 31, 2025. The company estimates it had approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. It also estimates net product revenue of $146.0 million for the fourth quarter of 2025 and $362.4 million for the full year 2025.
The company emphasized that these numbers are preliminary and subject to change as the year-end audit is completed. BridgeBio also presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, and made its presentation slides available as an exhibit and on its website.
BridgeBio Pharma, Inc. reported that it issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” The disclosure was made in connection with a current report and the press release is attached as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO. The report is dated October 29, 2025 and was signed by the President and Chief Financial Officer. Investors can refer to Exhibit 99.1 for the full press release text.
BridgeBio Pharma, Inc. furnished a press release reporting recent business updates and financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 29, 2025. The company noted that the information in Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act.
BridgeBio Pharma (BBIO) filed a Form 8-K announcing it issued a press release titled “BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study.” The press release is furnished as Exhibit 99.1 and is incorporated by reference. This 8-K provides notice of the clinical update; detailed results are contained in the attached exhibit.
BridgeBio Pharma, Inc. filed a Form 8-K reporting corporate documentation updates. The filing lists a Certificate of Amendment to the Amended and Restated Certificate of Incorporation and the Second Amended and Restated 2021 Stock Option and Incentive Plan with form award agreements as exhibits. The cover page identifies the company, ticker (BBIO), Nasdaq listing and corporate contact details. The document includes an interactive data file reference and is signed by the company’s Chief Legal Officer and Secretary.